Natixis Advisors, L.P. Catalyst Pharmaceuticals, Inc. Transaction History
Natixis Advisors, L.P.
- $63 Billion
- Q2 2025
A detailed history of Natixis Advisors, L.P. transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Natixis Advisors, L.P. holds 72,143 shares of CPRX stock, worth $1.5 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
72,143
Previous 62,990
14.53%
Holding current value
$1.5 Million
Previous $1.53 Million
2.49%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding CPRX
# of Institutions
388Shares Held
103MCall Options Held
0Put Options Held
277K-
Black Rock Inc. New York, NY18.7MShares$389 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.77MShares$183 Million0.0% of portfolio
-
State Street Corp Boston, MA5.48MShares$114 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny3.25MShares$67.7 Million0.1% of portfolio
-
Morgan Stanley New York, NY3.18MShares$66.3 Million0.0% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.14B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...